MA40929A - Procédé de production d'anticorps à affinité élevée - Google Patents

Procédé de production d'anticorps à affinité élevée

Info

Publication number
MA40929A
MA40929A MA040929A MA40929A MA40929A MA 40929 A MA40929 A MA 40929A MA 040929 A MA040929 A MA 040929A MA 40929 A MA40929 A MA 40929A MA 40929 A MA40929 A MA 40929A
Authority
MA
Morocco
Prior art keywords
antigen
antibodies
cells
production process
lymphoid
Prior art date
Application number
MA040929A
Other languages
English (en)
Inventor
Robert Babb
Gang Chen
James P Fandl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA40929A publication Critical patent/MA40929A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé d'identification de cellules qui expriment des anticorps spécifiques d'antigènes avec une forte affinité de liaison pour un antigène monomère. En utilisant un tri cellulaire activé par fluorescence, les cellules exprimant des anticorps spécifiques d'antigène à haute affinité sont sélectionnées à partir d'une population de cellules immunitaires isolées d'un mammifère qui a été immunisé ou exposé à l'antigène. Les acides nucléiques codant pour les anticorps à haute affinité peuvent ensuite être clonés dans d'autres cellules lymphoïdes et non lymphoïdes où l'anticorps peut être exprimé et à partir desquelles les anticorps peuvent être sécrétés.
MA040929A 2014-11-14 2015-11-13 Procédé de production d'anticorps à affinité élevée MA40929A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462079899P 2014-11-14 2014-11-14

Publications (1)

Publication Number Publication Date
MA40929A true MA40929A (fr) 2017-09-20

Family

ID=54754774

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040929A MA40929A (fr) 2014-11-14 2015-11-13 Procédé de production d'anticorps à affinité élevée

Country Status (6)

Country Link
US (4) US10752698B2 (fr)
EP (2) EP3218396B1 (fr)
DK (1) DK3218396T3 (fr)
ES (1) ES2939555T3 (fr)
MA (1) MA40929A (fr)
WO (1) WO2016077666A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3218396B1 (fr) * 2014-11-14 2022-12-28 Regeneron Pharmaceuticals, Inc. Procédé de production d'anticorps à affinité élevée
CN111351935A (zh) * 2018-12-20 2020-06-30 上海恒润达生生物科技有限公司 Bcma-car亲和力检测方法
CN116003590A (zh) * 2020-08-06 2023-04-25 熙源安健医药（上海）有限公司 抗ngf抗体及其抗原结合片段、其制备方法和应用
JP2024501796A (ja) * 2020-12-23 2024-01-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 膜貫通タンパク質に結合する抗体、および抗体を産生する細胞を取得する方法
MX2023012300A (es) 2021-04-20 2023-10-26 Regeneron Pharma Anticuerpos humanos contra artemina y metodos de uso de estos.
US20240316169A1 (en) 2021-07-05 2024-09-26 Regeneron Pharmaceuticals, Inc. Utilization of antibodies to shape antibody responses to an antigen
CA3235627A1 (fr) * 2021-10-18 2023-04-27 Byomass Inc. Anticorps anti-activine a, compositions et utilisations de ceux-ci
WO2023147107A1 (fr) * 2022-01-31 2023-08-03 Byomass Inc. Affections myéloprolifératives
WO2024015816A1 (fr) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Anticorps dirigés contre le récepteur du facteur neurotrophique ciliaire (cntfr) et leurs procédés d'utilisation
US20240345083A1 (en) * 2023-03-15 2024-10-17 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibody molecules with high affinity
WO2025175082A1 (fr) * 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Procédés permettant d'obtenir des cellules produisant des anticorps

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050048578A1 (en) * 2003-06-26 2005-03-03 Epitomics, Inc. Methods of screening for monoclonal antibodies with desirable activity
US8497138B2 (en) * 2010-09-30 2013-07-30 Genetix Limited Method for cell selection
DK2646466T3 (en) * 2010-12-02 2017-06-06 Aimm Therapeutics Bv METHODS AND METHODS FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
GB201316644D0 (en) 2013-09-19 2013-11-06 Kymab Ltd Expression vector production & High-Throughput cell screening
EP3218396B1 (fr) * 2014-11-14 2022-12-28 Regeneron Pharmaceuticals, Inc. Procédé de production d'anticorps à affinité élevée

Also Published As

Publication number Publication date
ES2939555T3 (es) 2023-04-24
US20240036043A1 (en) 2024-02-01
US12480947B2 (en) 2025-11-25
EP3218396A1 (fr) 2017-09-20
US20200369783A1 (en) 2020-11-26
US10752698B2 (en) 2020-08-25
US11808766B2 (en) 2023-11-07
WO2016077666A1 (fr) 2016-05-19
US20260049987A1 (en) 2026-02-19
EP4134378A1 (fr) 2023-02-15
EP3218396B1 (fr) 2022-12-28
US20170327593A1 (en) 2017-11-16
DK3218396T3 (da) 2023-03-06

Similar Documents

Publication Publication Date Title
MA40929A (fr) Procédé de production d'anticorps à affinité élevée
Moreau et al. Dynamic in situ cytometry uncovers T cell receptor signaling during immunological synapses and kinapses in vivo
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
WO2015112626A8 (fr) Capacité améliorée de présentation de l'antigène de lymphocytes t de récepteur d'antigène chimérique (car) par l'introduction conjointe de molécules de stimulation conjointe
EA202091566A1 (ru) Содержащая нуклеиновую кислоту липидная наночастица и ее применение
ZA201703241B (en) Anti-c5 antibodies and methods of use
MA42542B1 (fr) Molécules se liant à pd-1 et méthodes d'utilisation correspondantes
MA41287A (fr) Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement
PE20200839A1 (es) Anticuerpos anti-cd137
SA518391704B1 (ar) C5 أجسام مضادة لـ وطرق لاستخدامها
MA49355A (fr) Formats de récepteurs de liaison d'antigène améliorés
EA033433B1 (ru) Антитела к tau и их применение
AR109451A1 (es) Composiciones y métodos para preparar anticuerpos basados en el uso de loci mejoradores de expresión
CU20190087A7 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
MY187848A (en) Anti-c5 antibodies and methods of use
EA202091569A1 (ru) Моноклональные антитела и способы их применения
MX2024010986A (es) Anticuerpos monoclonales de adn dirigidos a moleculas de punto de control.
JOP20200215A1 (ar) الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها
AR098126A1 (es) Anticuerpos anti-ly6e (locus e del complejo del antígeno 6 linfocítico), inmunoconjugados y métodos para usarlos
JOP20190246A1 (ar) جسم مضاد أحادي النسيلة لـ pd-l1
MX353464B (es) Antigenos tpn47 de treponema pallidum, inmunoreactivos, solubles.
CU20180129A7 (es) Anticuerpos anti-basigin humanizados
WO2017176950A3 (fr) Vaccin contre le ver du cœur, procédés et utilisations associés
MX2017005644A (es) Variantes de antigeno trypanosoma cruzi jl7 recombinante y su uso para detectar la enfermedad de chagas.
UA124330C2 (uk) Спосіб кількісного визначення антирабічного антигену in vitro в інактивованих антирабічних вакцинах